Osphos – 15 ml

Bisphosphonate: Clodronate disodium (OSPHOS) is a non-amino, chloro-containing bisphosphonate. Chemically, clodronate disodium is (dichloromethylene) diphosphonic acid disodium salt and is manufactured from the tetrahydrate form. The structural formula of clodronate disodium is: Molecular Formula: CH2CL2O6 P2.2Na Molecular Weight: 288.85 Active substance clodronate disodium tetrahydrate 74.98 mg/mL corresponds to clodronate disodium 60.0 mg/mL. Each mL contains 60 mg clodronate disodium, sodium hydroxide (to adjust pH) and water for injection.

INDICATION

For the control of clinical signs associated with navicular syndrome in horses. DOSAGE AND

ADMINISTRATION

Administer 1.8 mg/kg by intramuscular injection up to a maximum dose of 900 mg per horse. Divide the total volume evenly into three separate injection sites. Discard unused vial contents. OSPHOS is provided in a single use vial and does not contain a preservative. Clinical improvement is most evident at 2 months post-treatment (see Effectiveness). Of the horses that responded to treatment with OSPHOS in the eld study, 65% maintained their level of improvement through the 6 month evaluation. If there is no response to initial therapy, the horse should be re-evaluated. For horses that initially respond to OSPHOS but do not maintain their clinical improvement for 6 months, OSPHOS may be re-administered at 3 to 6 month intervals based on recurrence of clinical signs. For horses that respond to OSPHOS and maintain clinical improvement for 6 months, OSPHOS should be re-administered after clinical signs recur.

CONTRAINDICATIONS

Horses with hypersensitivity to clodronate disodium should not receive OSPHOS.

WARNING

Do not use in horses intended for human consumption.

HUMAN WARNINGS

Not for human use. Keep this and all drugs out of the reach of children. Consult a physician in case of accidental human exposure.